Graham Capital Management, L.P. Eli Lilly & CO Transaction History

Graham Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	SELL	$525.19 - $619.13 $1.43 Million - $1.69 Million	-2,727 Reduced 56.49%	2,100 $1.22 Million
Q3 2023 Nov 22, 2023	BUY	$434.7 - $599.3 $2.1 Million - $2.89 Million	4,827 New	4,827 $2.59 Million
Q1 2023 May 15, 2023	BUY	$310.63 - $364.82 $1.76 Million - $2.07 Million	5,677 Added 841.04%	6,352 $2.18 Million
Q4 2022 Feb 14, 2023	SELL	$321.55 - $374.67 $467,533 - $544,770	-1,454 Reduced 68.29%	675 $246,000
Q3 2022 Nov 14, 2022	BUY	$296.48 - $337.87 $631,205 - $719,325	2,129 New	2,129 $688,000

4,007

752M

8.27M

10.5M

Ticker LLY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 950,174,976
Market Cap $750B
Description
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...

Get notified when there are updates to the investment portfolio of Graham Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Graham Capital Management, L.P. with notifications on news.